Linux users could face European patent threat: related news

Biopure Corporation wins European patent challenge

Add our medical news to digg - Biopure Corporation wins European patent challenge Add our medical news to NewsVine - Biopure Corporation wins European patent challenge Add our medical news to Fark - Biopure Corporation wins European patent challenge Add our medical news to Furl - Biopure Corporation wins European patent challenge Add our medical news to Shadows - Biopure Corporation wins European patent challenge Add our medical news to YahooMyWeb - Biopure Corporation wins European patent challenge Add our medical news to Reddit -Biopure Corporation wins European patent challenge Add our medical news to StumbleUpon - Biopure Corporation wins European patent challenge Add our medical news to Facebook - Biopure Corporation wins European patent challenge

U.S. Patent Office allows another significant VNUS patent

Add our medical news to digg - U.S. Patent Office allows another significant VNUS patent Add our medical news to NewsVine - U.S. Patent Office allows another significant VNUS patent Add our medical news to Fark - U.S. Patent Office allows another significant VNUS patent Add our medical news to Furl - U.S. Patent Office allows another significant VNUS patent Add our medical news to Shadows - U.S. Patent Office allows another significant VNUS patent Add our medical news to YahooMyWeb - U.S. Patent Office allows another significant VNUS patent Add our medical news to Reddit -U.S. Patent Office allows another significant VNUS patent Add our medical news to StumbleUpon - U.S. Patent Office allows another significant VNUS patent Add our medical news to Facebook - U.

Linux users could face European patent threat

Linux users in the UK could face a greater threat from Microsoft than previously thought, but experts agree that British open-source users are in far less danger than US users from Microsoft's claim that open-source software infringes its patents.

Kernel Devs Publish Position Statement on Linux Kernel Modules

We, the undersigned Linux kernel developers, consider any closed-source Linux kernel module or driver to be harmful and undesirable. We have repeatedly found them to be detrimental to Linux users, businesses, and the greater Linux ecosystem. Such modules negate the openness, stability, flexibility, and maintainability of the Linux development model and shut their users off from the expertise of the Linux community. Vendors that provide closed-source kernel modules force their customers to give up key Linux advantages or choose new vendors. Therefore, in order to take full advantage of the cost savings and shared support benefits open source has to offer, we urge vendors to adopt a policy of supporting their customers on Linux with open-source kernel code.

Biopure Wins European Patent Challenge

CAMBRIDGE, Mass., May 19, 2008 /PRNewswire-FirstCall/ -- Biopure Corporation announced today that it has successfully defended a challenge at the European Patent Office (EPO) to its European Patent entitled, "A Method for Chromatographic Removal of Prions." This European Patent covers Biopure's innovative purification method for removing potentially infectious prion proteins from oxygen therapeutics and provides Biopure with granted patent rights to its method in France, Germany, the United Kingdom, Ireland, Italy, Spain, and Switzerland. The Opposition Division of the EPO supported Biopure's rights to all of the claims originally granted by the EPO without any modifications or restrictions. The patent challenge was brought in an Opposition by Switzerland-based Octapharma AG.

Biopure Wins European Patent Challenge

CAMBRIDGE, Mass., May 19 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it has successfully defended a challenge at the European Patent Office (EPO) to its European Patent entitled, "A Method for Chromatographic Removal of Prions." This European Patent covers Biopure's innovative purification method for removing potentially infectious prion proteins from oxygen therapeutics and provides Biopure with granted patent rights to its method in France, Germany, the United Kingdom, Ireland, Italy, Spain, and Switzerland. The Opposition Division of the EPO supported Biopure's rights to all of the claims originally granted by the EPO without any modifications or restrictions. The patent challenge was brought in an Opposition by Switzerland-based Octapharma AG.

Biopure Wins European Patent Challenge

CAMBRIDGE, Mass., May 19 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR - News) announced today that it has successfully defended a challenge at the European Patent Office (EPO) to its European Patent entitled, "A Method for Chromatographic Removal of Prions." This European Patent covers Biopure's innovative purification method for removing potentially infectious prion proteins from oxygen therapeutics and provides Biopure with granted patent rights to its method in France, Germany, the United Kingdom, Ireland, Italy, Spain, and Switzerland. The Opposition Division of the EPO supported Biopure's rights to all of the claims originally granted by the EPO without any modifications or restrictions. The patent challenge was brought in an Opposition by Switzerland-based Octapharma AG.

Linux Desktop

Linux desktop news, tips and how-tos for value-added resellers (VARs), solution providers, consultants and systems integrators helping customers select, install and manage Linux desktops. You'll find expert advice, best practices and tutorials to help you manage and support Linux desktops, including information on choosing Linux distributions and platforms, offering Linux desktop support services, configuring Linux desktops, migrating to Linux, the advantages of Linux for the desktop and more open source considerations and channel opportunities around the Linux desktop.

Barr confirms patent challenge of Prevacid SoluTab tablets

Add our medical news to digg - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to NewsVine - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Fark - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Furl - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Shadows - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to YahooMyWeb - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Reddit -Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to StumbleUpon - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Facebook - Barr confirms patent challenge of Prevacid SoluTab tablets

Barr confirms Entocort patent challenge

Add our medical news to digg - Barr confirms Entocort patent challenge Add our medical news to NewsVine - Barr confirms Entocort patent challenge Add our medical news to Fark - Barr confirms Entocort patent challenge Add our medical news to Furl - Barr confirms Entocort patent challenge Add our medical news to Shadows - Barr confirms Entocort patent challenge Add our medical news to YahooMyWeb - Barr confirms Entocort patent challenge Add our medical news to Reddit -Barr confirms Entocort patent challenge Add our medical news to StumbleUpon - Barr confirms Entocort patent challenge Add our medical news to Facebook - Barr confirms Entocort patent challenge

EntreMed receives new patent for 2-Methoxyestradiol analogs

Add our medical news to digg - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to NewsVine - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Fark - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Furl - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Shadows - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to YahooMyWeb - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Reddit -EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to StumbleUpon - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Facebook - EntreMed receives new patent for 2-Methoxyestradiol analogs

Mylan wins generic Prilosec patent litigation

Add our medical news to digg - Mylan wins generic Prilosec patent litigation Add our medical news to NewsVine - Mylan wins generic Prilosec patent litigation Add our medical news to Fark - Mylan wins generic Prilosec patent litigation Add our medical news to Furl - Mylan wins generic Prilosec patent litigation Add our medical news to Shadows - Mylan wins generic Prilosec patent litigation Add our medical news to YahooMyWeb - Mylan wins generic Prilosec patent litigation Add our medical news to Reddit -Mylan wins generic Prilosec patent litigation Add our medical news to StumbleUpon - Mylan wins generic Prilosec patent litigation Add our medical news to Facebook - Mylan wins generic Prilosec patent litigation

Environmental Control Corporation Acquires Second Canadian Patent

VANCOUVER, BC -- 05/20/08 -- Environmental Control Corporation ("EVCC") (OTCBB: EVCC) -- It is with great pleasure that Environmental Control Corporation ("EVCC") (OTCBB: EVCC) announces the approval of its second Canadian Patent. The Reverse Flow Catalytic Muffler, Canadian Patent # 2,448,648, now accompanies Canadian Patent # 2,448,742 -- The Combined Catalytic Muffler. Other intellectual property currently held by EVCC includes two U.S. Patents: The Reverse Flow Catalytic Muffler (U.S. Patent # 7,018,590) and The Combined Catalytic Muffler (U.S. Patent # 6,622,482); and one pending patent in Europe: the Reverse Flow Catalytic Muffler (Patent Application # 02742591.7). It is anticipated that the European patent application will be approved and registered in the near future.

Biopure Wins European Patent Challenge

PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it has successfully defended a challenge at the European Patent Office (EPO) to its European Patent entitled, "A Method for Chromatographic Removal of Prions." This European Patent covers Biopure's innovative purification method for removing potentially infectious prion proteins from oxygen therapeutics and provides Biopure with granted patent rights to its method in

Kernel Developers Issue Joint Statement on Device Drivers

"We, the undersigned Linux kernel developers, consider any closed-source Linux kernel module or driver to be harmful and undesirable. We have repeatedly found them to be detrimental to Linux users, businesses, and the greater Linux ecosystem. Such modules negate the openness, stability, flexibility, and maintainability of the Linux development model and shut their users off from the expertise of the Linux community. Vendors that provide closed-source kernel modules force their customers to give up key Linux advantages or choose new vendors. Therefore, in order to take full advantage of the cost savings and shared support benefits open source has to offer, we urge vendors to adopt a policy of supporting their customers on Linux with open-source kernel code.

Windows-Linux Integration

"The use of Linux is no longer the sole preserve of IT administrators and tech-savvy computer users. Linux can now easily be incorporated into your environment without even having to go through the hassle of re-partitioning a disk. My previous article on VMWare illustrates that Linux is now pretty much a tool for everyone to use. However, one argument often made against the use of Linux is the difficulty of managing it. For instance, can you easily store and retrieve files on a Linux machine? Also, what about the problem of just interacting with and running the Linux machine? Isn't keeping up to date with Linux security patches a big problem? These are all good questions that I answer in the remainder of this article.

Nintendo Loses Patent Suit In East Texas, Of Course

The latest in a long line of patent lawsuits in every patent hoarders favorite district of East Texas involves the game controllers used by Nintendo. A company holds a patent on a 3D controller and sued Nintendo (and Microsoft) for supposedly violating the patent. Not surprisingly, the jury found in favor of the patent holder. Juries quite often side with the patent holder, no matter how questionable the patent may be. In this case, there would seem to be a ton of prior art raising validity questions. The patent itself was filed in November of 2000, at which point there were already numerous game controllers that seem to meet most of the criteria outlined in the claims. Whatever minor differences there may have been between what was on the market and what's in the claims should be seen as an obvious iteration of game controllers.

Avnet Launches MicroBlaze Processor Linux Design Solution

Avnet Inc. has released its Xilinx MicroBlaze Processor Linux DVD, MicroBlaze Processor Linux Starter Kit and the launch of the Linux for MicroBlaze Processor SpeedWay Design Workshop. The stand-alone Linux for MicroBlaze Processor DVD is based on both PetaLogix Petalinux and LynuxWork’s BlueCAT Linux distribution and tool chains. The DVD demonstrates how to port Linux into a Field Programmable Gate Array (FPGA) design using the 32-bit Xilinx MicroBlaze processor. It also highlights the benefits and tradeoffs when using the Memory Management Unit (MMU) in the MicroBlaze processor. The MMU enables designers to use commercial-grade operating systems when implementing their embedded designs with Xilinx FPGAs. The MicroBlaze Processor Linux Starter Kit includes the Linux for MicroBlaze Processor DVD, the Xilinx Embedded Development Kit - Spar

febit receives U.S. patent for microfluidic extraction method

Add our medical news to digg - febit receives U.S. patent for microfluidic extraction method Add our medical news to NewsVine - febit receives U.S. patent for microfluidic extraction method Add our medical news to Fark - febit receives U.S. patent for microfluidic extraction method Add our medical news to Furl - febit receives U.S. patent for microfluidic extraction method Add our medical news to Shadows - febit receives U.S. patent for microfluidic extraction method Add our medical news to YahooMyWeb - febit receives U.S. patent for microfluidic extraction method Add our medical news to Reddit -febit receives U.S. patent for microfluidic extraction method Add our medical news to StumbleUpon - febit receives U.S. patent for microfluidic extraction method Add our medical news to Facebook - febit receives U.

AMD's New Card Supports Linux From the Get-Go

Michael writes "Back in September AMD had announced a new ATI Linux driver as well as opening up their GPU specifications, and today they have taken an additional step to better support the Linux OS. With the just-announced Radeon HD 4850 RV770 they have provided same-day Linux support, and the Linux driver is now shipping alongside the Windows driver on their product CDs. In addition, they are encouraging their AIB partners to showcase Tux on the product packaging as a sign of Linux support. Last but certainly not least, AMD is committed from top-to-bottom product support on Linux and they will be introducing high-end features in their Linux driver such as MultiGPU CrossFire technology. Phoronix has a run-down on AMD's evolutionary leap in Linux support along with information on the open-source support for the RV770 GPU.

U.S. Patent on Cytori's Celution System Technology Issued; Celution System Commercialization not Impacted by Recent 6,777,231 Patent Inventorship Decision

SAN DIEGO--(BUSINESS WIRE)--Jun 24, 2008 - U.S. Patent No. 7,390,484 ("the '484 patent") covering Cytori's (NASDAQ:CYTX) Celution(R) System technology was issued today by the United States Patent and Trademark Office. The '484 patent provides Cytori critical market protection for its commercialization of the Celution System in the United States, where the Company is seeking regulatory approval. The '484 patent also protects Cytori's rights to manufacture the Celution Systems in the United States for commercialization into all markets, including Europe and Asia-Pacific, where the device is currently being sold. Other related patent filings are in progress around the globe.

Cedega Game Emulation Software Now Available to Desktop Linux Users at CNR.com

SAN DIEGO, May 15 /PRNewswire/ -- Linspire, Inc., developer of CNR.com, an easy-to-use, one-click digital software delivery service for desktop Linux software, and TransGaming, Inc. (TSX-V: TNG), a leading developer of portability and graphics technologies for the electronic entertainment industry, today announced the immediate availability of Cedega 6.0 for Freespire 2.0, Linspire 6.0, Linux Mint 4.0, Ubuntu 7.04, 7.10 and 8.04 (32 bit) desktop Linux users. Available at an introductory price of $44.95 and for download and installation with one-click through CNR.com, Cedega brings the thrill of blockbuster video games to Linux users around the world (http://www.cnr.com/product/transgamingcedega).

European software patents via treaty?

PRESS RELEASE -- [ Europe / Economy / Innovation ] ======================================================================== McCreevy wants to legalise Software Patents via a US-EU patent treaty ======================================================================== Brussels, 13 May 2008 -- European Commissioner McCreevy is pushing for a bilateral patent treaty with the United States. This Tuesday 13 May in Brussels, White House and European representatives will try to adopt a tight roadmap for the signature of a EU-US patent treaty by the end of the year. Parts of the proposed treaty will contain provision on software patents, and could legalise them on both sides of the Atlantic. "TEC talks are the current push for software patents. The US want to eliminate the higher standards of the European Patent Convention.

Novell Suse Linux Professional 9.3

Novell has released Suse Linux Professional 9.3, the new version of its Linux retail product. Novell promises the latest version takes the Linux home enthusiast to a new level of ease of use and system performance. With a complete Linux operating system, productivity software, and home networking capabilities, Suse Linux Professional 9.3 provides both the advanced applications tools that experienced users demand, as well as the ease of installation and security Novell says newcomers to Linux desire.

NICE Updates on Patent Infringement Litigation Brought Against Verint; Court Reaffirms...

NICE Updates on Patent Infringement Litigation Brought Against Verint; Court Reaffirms Validity of NICE's Patent RA'ANANA, Israel, May 26 /PRNewswire-FirstCall/ -- NICE Systems (NASDAQ: NICE) announced today that in a patent infringement case brought against Verint Americas, Inc. (formerly Witness Systems, Inc.) in the Federal District Court for Northern Georgia in Atlanta, the court found that certain Witness products, which were named in this case, do not infringe NICE's VoIP patent 6871229. NICE intends to appeal this decision. The court rejected Verint's claims challenging the validity of NICE's patent and reaffirmed its validity. The US Patent Office has also, prior to the trial, denied Verint's request for re-examination of the same patent.

Search took 0.65 seconds.